Israel-based biotech pioneer Senseera has successfully raised $7.1 million in a Seed funding round led by Lightspeed Venture Partners, with additional support from I-Next Capital and the Lowy Medical Research Institute. The investment aims to propel the development of Senseera’s GEM BIOMARKERS liquid biopsy platform, a groundbreaking tool that delivers biopsy-level precision through a simple blood test.
The platform, which utilizes cutting-edge cfChIP-seq technology, deciphers cell-specific gene expression and cell states from blood samples. This innovation offers a transformative approach to diagnosing and managing critical conditions like liver diseases, oncology, immunology, and metabolic disorders. By replacing invasive and nonspecific diagnostic methods, Senseera’s technology is poised to improve early detection and monitoring for diseases such as MASLD/MASH (formerly NAFLD/NASH), liver transplant rejection, and hepatocellular carcinoma (HCC).
“Current diagnostic tools for liver diseases often fall short in accuracy and timeliness, leading to delayed diagnoses and compromised patient care,” said Dr. Ronen Sadeh, CEO of Senseera. “Our platform provides a non-invasive solution that not only addresses these gaps but also holds immense potential to enhance patient outcomes across a wide spectrum of diseases.”
The funding will enable Senseera to accelerate the clinical development of its next-generation liver transplant rejection test, broaden its clinical trial efforts, and strengthen partnerships with global biopharma companies. Beyond diagnostics, the GEM BIOMARKERS platform is positioned as a pivotal tool for advancing drug development, especially in cancer and immune disorders, by shedding light on the interactions between immune cells and solid tissues.
“This funding represents a significant milestone for Senseera and the advancement of precision medicine,” said Dr. Sadeh. “With the support of Lightspeed and our other investors, we are well-equipped to expand our pipeline, foster collaborations, and deliver groundbreaking solutions to improve patient care worldwide.”
Senseera’s platform is built on decades of research spearheaded by Prof. Nir Friedman, whose work has been featured in leading scientific journals like Nature Biotechnology. The foundation of the company’s innovation is bolstered by data derived from over 20,000 human samples.
The GEM BIOMARKERS liquid biopsy platform represents a leap forward in non-invasive diagnostics, offering a versatile solution for early detection and disease monitoring in a global healthcare landscape that demands innovative and effective tools. With this new funding, Senseera is poised to redefine the future of diagnostics and patient care.
Discover more from FundingBlogger
Subscribe to get the latest posts sent to your email.